US 12,227,592 B2
Monoclonal antibody specifically binding to CCSP-2 and use thereof
Seung-Jae Myung, Seoul (KR); Eun-Ju Do, Seoul (KR); Jayoung Kang, Buan-gun (KR); Hye-Nam Son, Seoul (KR); Hyori Kim, Seoul (KR); A-Neum Lee, Seoul (KR); and Yeong Hui Cho, Hanam-si (KR)
Assigned to THE ASAN FOUNDATION, Seoul (KR); EDISBIOTECH CO., LTD., Seoul (KR); and UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, Ulsan (KR)
Appl. No. 17/310,296
Filed by THE ASAN FOUNDATION, Seoul (KR); EDISBIOTECH CO., LTD., Seoul (KR); and UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION, Ulsan (KR)
PCT Filed Jan. 29, 2020, PCT No. PCT/KR2020/001370
§ 371(c)(1), (2) Date Jul. 27, 2021,
PCT Pub. No. WO2020/159229, PCT Pub. Date Aug. 6, 2020.
Claims priority of application No. 10-2019-0011172 (KR), filed on Jan. 29, 2019.
Prior Publication US 2022/0089774 A1, Mar. 24, 2022
Int. Cl. C07K 16/00 (2006.01); C07K 16/32 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/32 (2013.01) [G01N 33/57492 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01)] 8 Claims
 
1. A monoclonal antibody specifically binding to the EGF2 domain of colon cancer secreted protein-2 (CCSP-2), which comprises heavy chain CDR1, 2, and 3 and light chain CDR1, 2, and 3,
wherein 1) the heavy chain CDR1, 2, and 3 comprises the amino acid sequence of SEQ ID NOs: 1, 2 and 3 respectively, and the light chain CDR1, 2, and 3 comprises the amino acid sequence of SEQ ID NOs: 4, 5, and 6 respectively, or
2) the heavy chain CDR1, 2, and 3 comprises the amino acid sequence of SEQ ID NOs: 13, 14, and 15 respectively, and the light chain CDR1, 2, and 3 comprises the amino acid sequence of SEQ ID NOs: 16, 17, and 18 respectively.